Literature DB >> 18343831

Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease.

Zizipho Z A Mbulawa1,2, Anna-Lise Williamson1,2, Debbie Stewart2, Jo-Ann S Passmore2, Lynette Denny3, Bruce Allan2, Dianne J Marais2.   

Abstract

We investigated neutralizing antibodies to human papillomavirus type 16 (HPV-16) in serum and cervical washes from 84 women with normal cytology or cervical disease. Serum neutralizing antibodies were detected in 78 % of women infected at the cervix with HPV-16, compared with 35 % (P=0.002) of women infected with HPV-16-related types (alpha9 HPV types), 14 % (P<0.0001) of women infected with HPV-16 non-related types and none of HPV-uninfected women. A significant correlation between HPV-16 infection and serum HPV-16-neutralizing antibodies was observed (r(s)=0.97; P=0.032). Cervical neutralizing antibodies were detected in 38 % of women with HPV-16 infection and in 17 % of women infected with the HPV-16-related type HPV-31. Cervical neutralizing antibodies correlated with HPV-16 infection (r(s)=0.95; P=0.08), but not with cervical disease. Serum and cervical HPV-16 antibody responses were not affected significantly by human immunodeficiency virus type 1 infection. In conclusion, serum and cervical HPV-16-neutralizing antibodies were found to correlate with HPV-16 infection, but not with cervical disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343831     DOI: 10.1099/vir.0.83458-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.

Authors:  Brenda Y Hernandez; Thien Ton; Yurii B Shvetsov; Marc T Goodman; Xuemei Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

2.  Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia.

Authors:  Hiroyuki Ochi; Kazunari Kondo; Koji Matsumoto; Akinori Oki; Toshiharu Yasugi; Reiko Furuta; Yasuo Hirai; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

3.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 4.  Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.

Authors:  Jade Pattyn; Severien Van Keer; Wiebren Tjalma; Veerle Matheeussen; Pierre Van Damme; Alex Vorsters
Journal:  Papillomavirus Res       Date:  2019-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.